Since there are not specific treatments available today for IMPC, the results exposed in this work indicate that the oncologist should subject patients to more frequent monitoring and other HER2-targeted treatments (i.e pertuzumab) and/or TNFα blocking strategies to provide a better outcome for HER2 positive/HR positive IMPC breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.